Compare · APR vs BSX
APR vs BSX
Side-by-side comparison of Apria Inc. (APR) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APR and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $71.85B, about 54.4x APR ($1.32B).
- BSX has hit the wire 12 times in the past 4 weeks while APR has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 6 for APR).
- Company
- Apria Inc.
- Boston Scientific Corporation
- Price
- $37.49-0.01%
- $48.34-1.25%
- Market cap
- $1.32B
- $71.85B
- 1M return
- -
- -9.40%
- 1Y return
- -
- -51.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 12
- Recent ratings
- 6
- 25
Apria Inc.
Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest APR
- SEC Form SC 13G/A filed by Apria Inc. (Amendment)
- SEC Form 15-12B filed by Apria Inc.
- Executives Sell Over $640M Of 5 Stocks
- SEC Form 4: Walker Robert P. returned $192,450 worth of shares to the company (5,132 units at $37.50), closing all direct ownership in the company (tax liability)
- SEC Form 4: Apria Holdings Llc sold $532,031,812 worth of shares (14,187,515 units at $37.50)
- SEC Form 4 filed by Snyder Lynn Shapiro to satisfy withholding obligation
- SEC Form 4: Scally Celina M. returned $166,425 worth of shares to the company (4,438 units at $37.50), closing all direct ownership in the company (tax withholding)
- SEC Form 4 filed by Lee Christopher G (withholding tax)
- SEC Form 4: Morris Debra L exercised 8,190 shares at a strike of $2.07, covered exercise/tax liability with 4,289 shares and returned $317,288 worth of shares to the company (8,461 units at $37.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Zafirovski Mike S returned $4,604,062 worth of shares to the company (122,775 units at $37.50), closing all direct ownership in the company (withholding tax)
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits